Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 1, 2011, Pages 139-148

  Cimini, E ^a,b   Piacentini, P ^a   Sacchi, A ^a   Gioia, C ^a   Leone, S ^b   Lauro, G M ^b   Martini, F ^a   Agrati, Chiara ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

Glioblastoma; Innate immunotherapy; T cells

Indexed keywords

ANTIGEN; CHEMOKINE; CYTOKINE; ISOPENTENYL DIPHOSPHATE; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PHOSPHOANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; KLRK1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOLYSIS; CYTOTOXICITY; DRUG ACTIVITY; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEMORY CELL; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE; TREATMENT RESPONSE; ANTINEOPLASTIC ACTIVITY; CELL DEATH; CELL KILLING; COCULTURE; CONTROLLED STUDY; GLIOMA CELL; GLIOMA CELL LINE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; BRAIN TUMOR; DRUG EFFECT; GLIOMA; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

BONE DENSITY CONSERVATION AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; GLIOMA; HUMANS; IMIDAZOLES; IMMUNOLOGIC MEMORY; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 79957859787     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400116     Document Type: Article

References (35)

1. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61:215-25. (Pubitemid 34212595)
2. Surawicz TS, Davis F, Freels S, Laws ER, Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 1998; 40:151-60. (Pubitemid 29010168)
3. DeAngelis LM. Chemotherapy for brain tumors - a new beginning. N Engl J Med 2005; 352:1036-8. (Pubitemid 40349508)
4. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-8. (Pubitemid 36152311)
5. Casetti R, Martino A. The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol 2008; 5:161-70.
6. Poccia F, Agrati C, Martini F, Capobianchi MR, Wallace M, Malkovsky M. Antiviral reactivities of gammadelta T cells. Microbes Infect 2005; 7:518-28.
7. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995; 154:3932-40.
8. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005; 174:1338-47.
9. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F. V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 2005; 175:5481-8. (Pubitemid 41456435)
10. Mariani S, Muraro M, Pantaleoni F, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19:664-70. (Pubitemid 40521173)
11. Viey E, Laplace C, Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2005; 5:973-86. (Pubitemid 43033787)
12. Bouet-Toussaint F, Cabillic F, Toutirais O, et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Imm Immunother 2008; 57:531-9. (Pubitemid 351170536)
13. Allen MR. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opin Drug Metab Toxicol 2008; 4:1371-8.
14. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97:840-7. (Pubitemid 36125821)
15. Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009; 58:31-8.
16. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67:7450-7. (Pubitemid 47206575)
17. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007; 56:469-76. (Pubitemid 46204533)
18. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102:200-6. (Pubitemid 36759655)
19. Burjanadze M, Condomines M, Reme T, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007; 139:206-16. (Pubitemid 47493076)
20. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008; 57:1599-609.
21. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63:8996-9006. (Pubitemid 38064081)
22. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96:6879-84. (Pubitemid 29274978)
23. Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS Jr. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol 2009; 11:357-67.
24. Bryant NL, Gillespie GY, Lopez RD, et al. Preclinical evaluation of ex vivo expanded/activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol 2010 (epub ahead of print).
25. Graaf MR, Richel DJ, Van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30:609-41. (Pubitemid 39451828)
26. Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98:71-108. (Pubitemid 36349762)
27. Farkkila M, Jaaskelainen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Paetau A, Sarelin H, Mantyla M. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 1994; 70:138-41. (Pubitemid 24203641)
28. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45:77-87. (Pubitemid 27497682)
29. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser DB, Shu S. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998; 89:42-51. (Pubitemid 28285921)
30. Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J Natl Cancer Inst 1996; 88:436-41.
31. Sturm E, Braakman E, Fisch P, Vreugdenhil RJ, Sondel P, Bolhuis RL. Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J Immunol 1990; 145:3202-8.
32. Yamaguchi T, Suzuki Y, Katakura R, Ebina T, Yokoyama J, Fujimiya Y. Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients. Cancer Immunol Immunother 1998; 47:97-103. (Pubitemid 28443560)
33. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. II-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human Vg9Vd2 T cells for adoptive immunotherapy. J Immunology 2009; 182:3423-31.
34. Lanca T, Correia DV, Moita CF, et al. The MHC class Ib protein ULBPl is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood 2010; 115:2407-11.
35. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20:117-20.